2020 年大参林医药集团股份有限 公司可转换公司债券2025年跟踪 评级报告 中鹏信评【2025】跟踪第【452】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级 ...

Core Viewpoint - The legal opinion issued by King & Wood Mallesons (Guangzhou) Law Firm confirms that the convening and holding of the 2025 First Extraordinary General Meeting of Dazhonglin Pharmaceutical Group Co., Ltd. complies with relevant laws, regulations, and the company's articles of association [1][4][10] Group 1: Meeting Procedures - The meeting was convened on June 25, 2025, and the notice was published in designated media including Securities Daily and the Shanghai Stock Exchange website [3][4] - The meeting took place at the Dazhonglin Group Comprehensive Building, with the presence of a majority of directors, and was chaired by Director Ke Guoqiang [5][6] Group 2: Attendance and Voting - A total of 374 participants attended the meeting, representing 782,247,723 shares, which is 69.0954% of the total voting shares [6][7] - The online voting involved 362 shareholders, representing 86,567,567 shares, accounting for 7.6464% of the total voting shares [7] - The qualifications of attendees were verified, confirming compliance with legal and regulatory requirements [8] Group 3: Voting Procedures and Results - The voting was conducted through a named voting method, with results announced post-voting [9] - The resolutions were passed with 862,239,871 votes in favor (99.2431%), 6,475,995 votes against (0.7453%), and 99,424 abstentions (0.0116%) [9]

Meeting Details - The shareholders' meeting was held on June 25, 2025, at the company's headquarters in Guangzhou [1] - The attendance rate of ordinary shareholders and preferred shareholders with restored voting rights was 76.7419% [1] - The meeting was convened by the board of directors and presided over by director Ke Guoqiang, following legal and procedural requirements [1] Voting Results - All non-cumulative voting proposals were approved, with 99.2431% of A-shareholders voting in favor [1] - The voting breakdown showed 862,239,871 votes in favor, 6,475,995 against, and 99,424 abstentions [1] Legal Compliance - The lawyers confirmed that the meeting's procedures complied with relevant laws and regulations, ensuring the legality of the attendees and the voting process [2]

Core Viewpoint - Dazhonglin has implemented a high dividend payout strategy, distributing a total of 7.02 billion yuan in cash dividends for the year, reflecting a strong commitment to shareholder returns and confidence in its operational strength amid market complexities [1][2]. Financial Performance - In 2024, Dazhonglin achieved a revenue of 26.497 billion yuan and a net profit attributable to shareholders of 915 million yuan [1]. - For the first quarter of 2025, the company reported a revenue of 6.956 billion yuan, representing a year-on-year growth of 3.02%, and a net profit of 460 million yuan, showing a year-on-year increase of 15.45% [1][2]. Dividend Policy - The company distributed a cash dividend of 3.1 yuan per 10 shares (including tax) to all shareholders, totaling 351 million yuan [1]. - Dazhonglin has maintained a high dividend payout ratio of 76.73%, with a dividend yield of 3.98%, ranking among the top in its sector [1][2]. - Since its listing in 2017, Dazhonglin has cumulatively distributed cash dividends amounting to 3.355 billion yuan, with a dividend payment ratio of 76.73% and a financing payout ratio of 98.84% [1]. Store Expansion and Market Position - As of March 2025, Dazhonglin operated a total of 16,622 stores, including 6,239 franchise stores and 10,383 direct stores, marking a net increase of 2,588 stores since the beginning of 2024 [2]. - The company aims to enhance its market share in already covered regions, leveraging its scale advantages to further solidify its position as a leading chain pharmacy in China [2]. Future Outlook - Dazhonglin is expected to strengthen its leadership in the pharmaceutical retail sector, driven by ongoing industry transformations and increasing consumer demand for quality and personalized health products [2].

证券代码：603233 证券简称：大参林 公告编号：2025-045 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 374 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 868,815,290 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 76.7419 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，经过半数董事推举，由董事柯国强主持本次股 东大会。会议采取现场投票及网络投票方式召开并表决。会议的召集和召开符合 《公司法》《上市公司股东大会规则》和《公司章程》等有关规定。 (一) 股东大会召开的时间：2025 年 6 月 25 日 (二) 股东大会召开的地点：广州市荔湾区龙溪大道 410 号大参林集团综合楼 4 楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先 ...

关于大参林医药集团股份有限公司 2025 年第一次临时股东大会的法律意见书 北京市金杜（广州）律师事务所 致：大参林医药集团股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受大参林医药集团股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境 内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中 国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件 和现行有效的公司章程有关规定，指派律师出席了公司于 2025 年 6 月 25 日召开 的 2025 年第一次临时股东大会（以下简称本次股东大会），并就本次股东大会相 关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1 1． 经公司 2024 年年度股东大会审议通过的《大参林医药集团股份有限公司 章程》（以下简称《公司章程》）； 2． 公司 2025 年 6 月 10 日刊登于《中国证券报》《证 ...

证券代码：603233 证券简称：大参林 公告编号：2025-044 大参林医药集团股份有限公司 关于公司控股股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担连带责任。 重要内容提示： 于其他保障用途。 3、股东累计质押股份情况 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下： 单位：股 股东 名称 是否 为控 股股 东 本次质押股 数（股） 是否为限售 股 是否 补充 质押 质押起始 日 质押到期 日 质权人 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 质押融 资资金 用途 柯康 保 是 15,000,000 否 否 2025 年 6 月 23 日 2026 年 6 月 24 日 兴业国际 信托有限 公司 8.42 1.32 个人用 途 合计 - 15,000,000 - - - - - 8.42 1.32 - 大参林医药集团股份有限公司（以下简称"公司"或"本公司"）控股股东 之一的柯康保先生持有公司无限售条件流通股178,192,742股，占公司总股 本的15.65%。 截至公告披露日 ...

Core Viewpoint - The company is preparing for its upcoming shareholder meeting scheduled for June 25, 2025, focusing on the election of a new non-independent director and ensuring compliance with relevant laws and regulations [2][3][5]. Meeting Details - The meeting will be held at the company's headquarters in Guangzhou, with both on-site and online voting options available for shareholders [2][3]. - The meeting will commence at 10:30 AM, with specific time slots allocated for online voting [2]. Agenda and Procedures - The agenda includes signing in, announcing the number of shareholders present, selecting vote counters, and discussing various proposals [2][3][4]. - Shareholders will have the opportunity to speak and vote on the proposals, with specific rules governing the speaking time and number of times a shareholder can speak [3][5]. Proposal for Director Election - A key proposal involves the election of Mr. Ke Tuoki as a non-independent director, nominated by the controlling shareholder Mr. Ke Yunfeng [5][6]. - Mr. Ke Tuoki has no current shareholding in the company and is related to Mr. Ke Yunfeng as his son, which aligns with the company's nomination regulations [5][6]. Qualifications of the Nominee - The nomination committee has reviewed Mr. Ke Tuoki's qualifications and confirmed that he meets the necessary criteria to serve as a director [6]. - There are no legal restrictions preventing him from holding the position, and he is not listed as a market disqualified individual by the China Securities Regulatory Commission [6].

2025 年第一次临时股东大会会议材料 大参林医药集团股份有限公司 2025 年第一次临时股东大会 会议材料 二○二五年六月 2025 年第一次临时股东大会会议材料 目 录 | 2025 | 年第一次临时股东大会会议议程 | 1 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议须知 | 3 | | 2025 | 年第一次临时股东大会会议议案 | 4 | | | 议案一：关于选举第四届董事会非独立董事的议案 | 4 | 2025 年第一次临时股东大会会议材料 大参林医药集团股份有限公司 2025 年第一次临时股东大会会议议程 会议表决方式：现场投票与网络投票相结合的方式 会议时间：2025 年 6 月 25 日上午 10 点 30 分 网络投票：2025 年 6 月 25 日 网络投票起止时间：采用上海证券交易所网络投票系统，通过交易系统投票 平台的投票时间为股东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 会议地点：广东省广州市荔湾区龙溪大道 41 ...

Core Viewpoint - Multiple securities firms, including Dongfang Securities, Zheshang Securities, and CITIC Securities, have issued positive ratings for Dazhenglin (603233.SH), highlighting its performance in 2024 and Q1 2025, business layout, and future prospects [1][2]. Group 1: Financial Performance - In 2024, Dazhenglin achieved a revenue of 26.497 billion yuan, representing a year-on-year growth of 8.01%, with a net profit attributable to shareholders of 915 million yuan [1]. - For Q1 2025, the company reported a revenue of 6.956 billion yuan, a year-on-year increase of 3.02%, and a net profit of 460 million yuan, reflecting a significant year-on-year growth of 15.45% and a remarkable quarter-on-quarter surge of 712.26% [1]. Group 2: Business Expansion and Network - As of March 2025, Dazhenglin operates a total of 16,622 stores, including 6,239 franchise stores and 10,383 direct-operated stores, covering 21 provinces across the country [2]. - The company plans to focus on optimizing its store network and accelerating franchise development in 2025, aiming to enhance market share and brand influence in underrepresented areas [2]. Group 3: Digital Transformation and New Retail - Dazhenglin is advancing its new retail channels and digital initiatives, with over 110 million private domain members and nearly 60 million active members as of the end of 2024 [3]. - The company has implemented an O2O delivery service with an 80.38% store coverage rate and is enhancing its online and offline integration through a "central warehouse + provincial warehouse + regional warehouse + store" model [3]. - The introduction of AI technology, such as "AI Xiaosan," aims to improve operational efficiency by providing accurate instant responses and intelligent analysis [3].